Summaries for Newborn Respiratory Distress Syndrome

Disease Ontology:11 A respiratory failure that is characterized by deficiency of the surfactant coating the inner surface of the lungs, by failure of the lungs to expand and contract properly during breathing with resulting collapse, and by the accumulation of a protein-containing film lining the alveoli and their ducts.

FDA approved drugs:

Indications and Usage:16 Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (ârescueâ) of premature infants who develop RDS. Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS. Prophylaxis Prophylaxis therapy at birth with Infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for RDS. Infasurf prophylaxis should be administered as soon as possible, preferably within 30 minutes after birth. Treatment Infasurf therapy is indicated for infants â¤72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.